Flying The Web For News.
  • Epiphany
    Epiphany
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: European Commission approves RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

Details
Category: Globe NewsWire News Distribution Service

This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line treatment of patients with EGFR-mutated NSCLC1 In the Phase 3 MARIPOSA study, amivantamab plus lazertinib significantly reduced the risk of disease progression or death by 30 percent versus osimertinib monotherapy1


Posted: 2024-12-30 08:00:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | european | commission | approves


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: European Commission approves RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer - Newscast

EU Approves Synopsys and Ansys Merger with Divestment Conditions

Mon, 13 Jan 2025 13:30:00 GMT The European Commission conditionally approved the $35 billion acquisition of simulation software company Ansys by Synopsys on Friday.

EU approves $35B Synopsys and Ansys merger, subject to divestment conditions

Fri, 10 Jan 2025 11:16:00 GMT The European Commission has given the green light for Synopsys to acquire Ansys in what will be a $35 billion transaction.

European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy

Thu, 09 Jan 2025 00:00:00 GMT BAAR, Switzerland, January 09, 2025--(BUSINESS WIRE)--Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has ...

European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy

Thu, 09 Jan 2025 00:00:00 GMT Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia ...

European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy

Wed, 08 Jan 2025 16:01:00 GMT BAAR, Switzerland — Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication ...


Blow Us A Whistle